

FIG 1




FIG 2




FIG 3







FIG 4




BRI6727




BRI6728



BRI6734




BRI6813




BRI6795


FIG 5A




BRI6796




BRI6797



BRI6798




BRI6799




BRI6800

FIG 5B


09945277-112601




BRI6801




BRI6802



BRIX114




BRI6803




BRI6814


FIG 5C




BRI6815




BRI6816



BRI6817




BRI6822




BRI6823


FIG 5D




BRI6824




BRI6825



BRI6829



BRI6855



BRI6856

FIG 5E










FIG 5F




BRI7009



BRI7012

FIG 5G


Inhibition or enhancement of FcγRIIa binding to human IgG1.



Serial dilutions of compounds at specified concentrations, prefix BRI and designated as indicated, were preincubated with receptor and injected over IgG and extent of receptor binding determined (shown as Response Units - Y axis).

FIG 6


Inhibition or enhancement of FcγRIIIa binding to human IgG3.



Serial dilutions of compounds at specified concentrations, prefix BRI and designated as indicated, were preincubated with receptor and injected over IgG and extent of receptor binding determined (shown as Response Units - Y axis).

FIG 7


Inhibition or enhancement of FcγRIIIa binding to human IgG1.



Serial dilutions of compounds at specified concentrations, prefix BRI and designated as indicated, were preincubated with receptor and injected over IgG and extent of receptor binding determined (shown as Response Units - Y axis).

FIG 8

Inhibition or enhancement of FcγRIIIa binding to human IgG3.



Serial dilutions of compounds at specified concentrations, prefix BRI and designated as Indicated, were preincubated with receptor and injected over IgG and extent of receptor binding determined (shown as Response Units - Y axis).

FIG 9

Enhanced sFcγRII binding




FIG 10

Inhibition of sFcγRIIIa binding






FIG 11



Activation of platelets in the presence of agonist only.
 Platelets ($100 \times 10^6/\text{ml}$) were mixed in the presence of $\text{Fc}\gamma\text{RIIIa}$ agonist (HAGG, $200 \mu\text{g}/\text{ml}$) and PBS and the rate of platelet aggregation was measured as the gradient of the change in percent light transmission (x) over time (y).

FIG 12



agonist and compound BRI 6855

Activation of platelets in the presence of agonist and BRI compound 6855. Platelets ($100 \times 10^6/\text{ml}$) were mixed in the presence of Fc γ RIIa agonist (HAGG, $200 \mu\text{g}/\text{ml}$) and compound BRI 6855 ($5 \text{ mg}/\text{ml}$) and the rate of platelet aggregation was measured as the gradient of the change to percent light transmission (x) over time (y).

FIG 13

Effect of BRI compound 6728 on platelet aggregation with HAGG




FIG 14